Abstract:Background & aims Nonalcoholic fatty liver disease (NAFLD) is a dynamic spectrum of chronic metabolic liver disease and ranges from simple steatosis to nonalcoholic steatohepatitis (NASH). However, the molecular mechanisms underlying steatosis-to-NASH progression remain incompletely understood. Methods In the present study, we investigated the profiling changes of MicroRNAs and identified miR-145a-5p as an important checkpoint in this process. In vivo loss-of-function and gain-of-function studies were performed to explore the role of miR-145a-5p and Nr4a2 in NASH progression. RNA-Sequencing and bioinformatic analysis were used to investigate the target of miR-145a-5p. Results Suppression of miR-145a-5p in the liver activated hepatic inflammation, liver injury and fibrosis in steatotic mice, whereas its restoration markedly attenuated diet-induced NASH pathogenesis. Mechanistically, miR-145a-5p was able to downregulate the nuclear receptor Nr4a2 to inhibit the expression of NASH-associated genes. Similarly, Nr4a2 overexpression promoted steatosis-to-NASH progression while liver-specific Nr4a2 knockout mice were protected from diet-induced NASH. Of potential clinical significance, the miR-145a-5p/Nr4a2 regulatory axis was also confirmed in human primary hepatocytes. Besides, expression level of miR-145a-5p was reduced and Nr4a2 was increased in the livers of NASH patients. Their expression levels were significantly correlated with hepatic pathological features. Conclusions Our findings highlight the role of miR-145a-5p/Nr4a2 regulatory axis in steatosis-to-NASH progression, suggesting that either supplementation of miR-145a-5p or pharmacological inhibition of Nr4a2 in hepatocytes may provide a promising therapeutic approach for treating NASH. Impact and implications Nonalcoholic fatty liver disease (NAFLD) is a dynamic spectrum of chronic liver disease ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). Unfortunately, there are currently no approved drugs for NASH. Our current study identified miR-145a-5p as a novel regulator that inhibits steatosis-to-NASH progression. We found that miR-145a-5p was able to downregulate the nuclear receptor Nr4a2 to suppress the expression of NASH-associated genes. The differentially expression of miR-145a-5p and Nr4a2 was further confirmed in patients with NASH, raising the possibility that supplementation of miR-145a-5p or suppression of Nr4a2 in hepatocytes might provide novel strategies for treating NASH.

mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance

MicroRNA-101 Suppresses Liver Fibrosis by Downregulating PI3K/Akt/mTOR Signaling Pathway

MiR-103-3p Promotes Hepatic Steatosis to Aggravate Nonalcoholic Fatty Liver Disease by Targeting of ACOX1

Mir-301A-3p Promotes Hepatic Stellate Cells Activation and Liver Fibrogenesis Via Regulating PTEN/PDGFR-β.

Aberrant Hepatic Microrna Expression in Nonalcoholic Fatty Liver Disease

Effect Of Mir-34a In Regulating Steatosis By Targeting Ppar Alpha Expression In Nonalcoholic Fatty Liver Disease

Effect of Mirna-10b in Regulating Cellular Steatosis Level by Targeting Ppar-Alpha Expression, A Novel Mechanism for the Pathogenesis of Nafld

Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease

Mir-149 Controls Non-Alcoholic Fatty Liver by Targeting Fgf-21

MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice

MicroRNA‐30b Regulates Insulin Sensitivity by Targeting SERCA2b in Non‐alcoholic Fatty Liver Disease

MiR-552-3p Regulates Multiple Fibrotic and Inflammatory genes Concurrently in Hepatic Stellate Cells Improving NASH-associated Phenotypes

MicroRNA-101 suppresses liver fibrosis by targeting the TGFβ signalling pathway.

MiR-182-5p Is Upregulated in Hepatic Tissues from a Diet-Induced NAFLD/NASH/HCC C57BL/6J Mouse Model and Modulates Cyld and Foxo1 Expression

MicroRNA-494-3p Prevents Liver Fibrosis and Attenuates Hepatic Stellate Cell Activation by Inhibiting Proliferation and Inducing Apoptosis Through Targeting TRAF3

Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR-155 deficient mice in a high fat-cholesterol-sugar diet-induced model of NASH

Anti-Liver Fibrosis Role of miRNA-96-5p via Targeting FN1 and Inhibiting ECM-Receptor Interaction Pathway

Mir-345–5P Curbs Hepatic Stellate Cell Activation and Liver Fibrosis Progression by Suppressing Hypoxia-Inducible Factor-1Alpha Expression

Inhibition of Mir-499-5p Expression Improves Nonalcoholic Fatty Liver Disease

Upregulation of Mir-181A Impairs Hepatic Glucose and Lipid Homeostasis.

Downregulation of microRNA-145a-5p promotes steatosis-to-NASH progression through upregulation of Nr4a2